ArticleBioinformation2025
Inflammatory and hematologic biomarker profiles across central branch and hemi-retinal vein occlusion.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baseline predictors of visual response and treatment burden after ranibizumab therapy in macular edema secondary to retinal vein occlusion.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal vein occlusion (RVO) is a common vision-threatening vascular disorder, yet reliable biomarkers to predict its severity at first presentation are lacking. Therefore, it is of interest to assess complete blood counts and fasting lipids within 24 hours of diagnosis of 50 newly diagnosed Retinal vein occlusion (RVO) eyes and 50 controls. Neutrophil-to-lymphocyte ratios (NLR), platelet-to-lymphocyte ratio (PLR) and monocyte-to-HDL ratio (MHR) were calculated; severity was graded clinically and angiographically. Logistic regression adjusted for age, hypertension, diabetes and LDL and Receiver-operating characteristics (ROC) determined optimal cut-offs. Simple ratios derived from a haemogram strongly predicted RVO severity independent of traditional risk factors. NLR and PLR could be incorporated into first-visit triage to prioritize fluorescein angiography and early anti-VEGF therapy in high-risk eyes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.